ATE421528T1 - Modifizierter typ-1-plasminogenaktivatorinhibitor und darauf beruhende verfahren - Google Patents

Modifizierter typ-1-plasminogenaktivatorinhibitor und darauf beruhende verfahren

Info

Publication number
ATE421528T1
ATE421528T1 AT03745086T AT03745086T ATE421528T1 AT E421528 T1 ATE421528 T1 AT E421528T1 AT 03745086 T AT03745086 T AT 03745086T AT 03745086 T AT03745086 T AT 03745086T AT E421528 T1 ATE421528 T1 AT E421528T1
Authority
AT
Austria
Prior art keywords
pai
modified
angiogenesis
plasminogen activator
analogs
Prior art date
Application number
AT03745086T
Other languages
English (en)
Inventor
Rafal Swiercz
Steven Selman
Jerzy Jankun
Ewa Skrzypczak-Jankun
Joanna Chorostowska-Wynimko
Original Assignee
Ohio Med College
Univ Toledo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohio Med College, Univ Toledo filed Critical Ohio Med College
Application granted granted Critical
Publication of ATE421528T1 publication Critical patent/ATE421528T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8132—Plasminogen activator inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
AT03745086T 2002-03-04 2003-03-04 Modifizierter typ-1-plasminogenaktivatorinhibitor und darauf beruhende verfahren ATE421528T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36167002P 2002-03-04 2002-03-04

Publications (1)

Publication Number Publication Date
ATE421528T1 true ATE421528T1 (de) 2009-02-15

Family

ID=28454581

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03745086T ATE421528T1 (de) 2002-03-04 2003-03-04 Modifizierter typ-1-plasminogenaktivatorinhibitor und darauf beruhende verfahren

Country Status (7)

Country Link
US (2) US7592422B2 (de)
EP (1) EP1487867B1 (de)
AT (1) ATE421528T1 (de)
AU (1) AU2003243134A1 (de)
CA (1) CA2481556C (de)
DE (1) DE60325946D1 (de)
WO (1) WO2003080646A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003243134A1 (en) * 2002-03-04 2003-10-08 Medical College Of Ohio Modified plasminogen activator inhibitor type-1 and methods based thereon
US8106002B2 (en) 2005-04-18 2012-01-31 Chugai Seiyaku Kabushiki Kaisha Anti-cancer agent comprising protein C inhibitor
WO2006122144A2 (en) * 2005-05-10 2006-11-16 Ludwig Institute For Cancer Research Methods and compositions for pdgf-d activation and inhibition
US8066991B2 (en) * 2005-10-11 2011-11-29 Amano Enzyme Usa Co., Ltd. Enzyme inhibitors of PAI-1
EP2150273A4 (de) * 2007-04-27 2010-11-17 Univ Toledo Modifiziertes plasminogenaktivatorhemmer-molekül vom typ 1 und verfahren zu seiner anwendung
WO2009045412A2 (en) * 2007-10-01 2009-04-09 American Diagnostica, Inc. Methods of treatment using modified plasminogen activator inhibitor type-1 molecules
WO2011086557A1 (en) * 2010-01-13 2011-07-21 Thrombotech Ltd. Peptides for the treatment of respiratory diseases
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
WO2011139974A2 (en) * 2010-05-03 2011-11-10 Abbott Laboratories Anti-pai-1 antibodies and methods of use thereof
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
AU2020388059A1 (en) * 2019-11-21 2022-06-23 The Regents Of The University Of Michigan Polypeptide inhibitors of neutrophil elastase activity and uses thereof
EP4435102A1 (de) * 2023-03-24 2024-09-25 AB Enzymes GmbH Screening-verfahren

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4980286A (en) * 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5679350A (en) * 1992-05-28 1997-10-21 The University Of Toledo Method of delivery of a medicament to a cancer cell using a pathway of plasminogen activator material
US5635493A (en) * 1993-12-01 1997-06-03 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine chemotherapeutics
US5639726A (en) 1994-09-30 1997-06-17 The Regents Of The University Of Michigan Peptide mediated enhancement of thrombolysis methods and compositions
EP0850252B1 (de) 1996-04-12 2005-06-08 American National Red Cross Mutierter plasminogen-aktivator-inhibitor typ 1 und seine verwendungen
US6303338B1 (en) 1996-08-16 2001-10-16 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
AU2003243134A1 (en) * 2002-03-04 2003-10-08 Medical College Of Ohio Modified plasminogen activator inhibitor type-1 and methods based thereon
JP2008515808A (ja) * 2004-10-04 2008-05-15 トリニティ バイオシステムズ インコーポレーテッド 針不用の高分子送達のための方法及び組成物
EP2150273A4 (de) * 2007-04-27 2010-11-17 Univ Toledo Modifiziertes plasminogenaktivatorhemmer-molekül vom typ 1 und verfahren zu seiner anwendung

Also Published As

Publication number Publication date
DE60325946D1 (de) 2009-03-12
WO2003080646A2 (en) 2003-10-02
EP1487867A4 (de) 2006-05-31
CA2481556A1 (en) 2003-10-02
EP1487867B1 (de) 2009-01-21
WO2003080646A3 (en) 2004-04-08
US20050158295A1 (en) 2005-07-21
US7592422B2 (en) 2009-09-22
EP1487867A2 (de) 2004-12-22
AU2003243134A1 (en) 2003-10-08
CA2481556C (en) 2014-04-29
US20100137209A1 (en) 2010-06-03

Similar Documents

Publication Publication Date Title
ATE421528T1 (de) Modifizierter typ-1-plasminogenaktivatorinhibitor und darauf beruhende verfahren
Masure et al. Purification and identification of 91‐kDa neutrophil gelatinase: Release by the activating peptide interleukin‐8
EA200501017A1 (ru) Астма и модуляторы аллергических воспалений
ATE279430T1 (de) Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülen
EA200100992A1 (ru) Ингибиторы фермента impdh
EA200200058A1 (ru) Пиримидин-2,4,6-трионовые ингибиторы металлопротеиназ
ATE411288T1 (de) Aryl-, aryloxy- und alkyloxysubstituierte 1h- indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
BRPI0412125A (pt) molécula de ácido nucleico isolada, polipeptìdeo de fusão, vetor de expressão, método de produzir um polipeptìdeo de fusão de vegf, captador de fator de crescimento de célula endotelial vascular, composição farmacêutica, método de tratar uma doença ou condição que são restabelecidas, melhoradas ou inibidas pela remoção ou inibição do fator de crescimento endotelial vascular, e, artigo de fabricação
EA200401541A1 (ru) АМИДЫ ЗАМЕЩЁННЫХ 3-АМИНОТИЕНО [2,3-b]ПИРИДИН-2-КАРБОНОВЫХ КИСЛОТ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
EA200300508A1 (ru) Противовоспалительные агенты
Gold et al. Human plasma fibronectin as a substrate for human urokinase
CY1107342T1 (el) Χρηση παραγωγων νιτριλιου ως φαρμακο
Suzuki Activated protein C inhibitor
Wyganowska-Świątkowska et al. The plasminogen activation system in periodontal tissue
De et al. Ubiquitin-like protein from human placental extract exhibits collagenase activity
Yoshida et al. Characterization of an apparently lower molecular weight gamma-chain variant in fibrinogen Kyoto I. The replacement of gamma-asparagine 308 by lysine which causes accelerated cleavage of fragment D1 by plasmin and the generation of a new plasmin cleavage site.
ES2113878T3 (es) Proteina c hibrida.
DK0458937T3 (da) Varianter af PAI-2
JPH0365151B2 (de)
EA200300066A1 (ru) Производные аминоалкоксибензоил-бензофурана или бензотиофена, способ их получения и содержащие их композиции
ATE361914T1 (de) Cathepsincysteinproteaseinhibitoren und deren verwendung zur behandlung von entzündungen und immunerkrankungen
Steinmetzer et al. Beyond Heparinization: Design of highly potent thrombin inhibitors suitable for surface coupling
DE60327228D1 (de) Verfahren zur herstellung von wachstumshormon und antagonisten davon mit geringeren konzentrationen an isoformen verunreinigungen davon
SG160194A1 (en) Truncated aggrecanase molecules
Righetti et al. Charge heterogeneity of recombinant pro-urokinase and urinary urokinase, as revealed by isoelectric focusing in immobilized pH gradients

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties